Physical Assessment

Both you and your physician will be monitoring the potential risks of letrozole.

The risks that may cause the most concern are:
- Decreases in bone mineral density (BMD).
- Increases in cholesterol.

The patient should be aware and notify the physician of any changes in how they feel, particularly paying attention to bone pain and liver pain (upper right quadrant).

The way to monitor these risks are through the following:
- bone density test
- complete blood cell counts (CBC)
- thyroid function tests
- monitoring serum electrolytes
- monitoring cholesterol and liver function tests, kidney function, and blood pressure.

There will also be the physical assessment of the patient. This will include blood pressure readings, pain assessment, gastrointestinal upsets, and hot flashes.

When initiating letrozole treatment, patients may experience dizziness and fatigue. Until your body adjusts be cautious before performing work that requires mental alertness, such as driving.

For more information, see the follwing links:

http://www.rxlist.com/femara-drug.htm
http://www.webmd.com/drugs/drug-4363-Femara+Oral.aspx?drugid=4363&drugname=Femara+Oral Both you and your physician will be monitoring the potential risks of letrozole.

The risks that may cause the most concern are:
- Decreases in bone mineral density (BMD).
- Increases in cholesterol.

The patient should be aware and notify the physician of any changes in how they feel, particularly paying attention to bone pain and liver pain (upper right quadrant).

The way to monitor these risks are through the following:
- bone density test
- complete blood cell counts (CBC)
- thyroid function tests
- monitoring serum electrolytes
- monitoring cholesterol and liver function tests, kidney function, and blood pressure.

There will also be the physical assessment of the patient. This will include blood pressure readings, pain assessment, gastrointestinal upsets, and hot flashes.

When initiating letrozole treatment, patients may experience dizziness and fatigue. Until your body adjusts be cautious before performing work that requires mental alertness, such as driving.

For more information, see the follwing links:

http://www.rxlist.com/femara-drug.htm
http://www.webmd.com/drugs/drug-4363-Femara+Oral.aspx?drugid=4363&drugname=Femara+Oral

Both you and your physician will be monitoring the potential risks of anastrozole.

The risks that may cause the most concern are:
- Decreases in bone mineral density (BMD). (Potential increase in bone loss.)
- May cause higher cholesterol levels or liver disease.
- Patient's with heart disease may have more of a chance to experience an ischemic cardiovascular event. (An ischemic cardiovascular event is reduced blood supply to the muscles of the heart).

The patient should be aware and notify the physician of any changes in how they feel, particularly paying attention to bone pain, chest pain, or liver pain (upper right quadrant).

The way to monitor these risks are through the following:
- bone density test
- complete blood cell counts (CBC)
- monitoring cholesterol and liver function tests
- thyroid function tests
- monitoring serum electrolytes
- kidney function, and blood pressure.


There will also be the physical assessment of the patient and monitoring for the postmenopausal women taking anastrozole. This will include blood pressure readings, pain assessment, gastrointestinal upsets, and hot flashes.

When initiating anastrozole treatment patients may experience dizziness and fatigue. Until your body adjusts be cautious before performing work that requires mental alertness, such as driving.

For more information, see the following link:
http://www.rxlist.com/arimidex-drug.htm Both you and your physician will be monitoring the potential risks of anastrozole.

The risks that may cause the most concern are:
- Decreases in bone mineral density (BMD). (Potential increase in bone loss.)
- May cause higher cholesterol levels or liver disease.
- Patient's with heart disease may have more of a chance to experience an ischemic cardiovascular event. (An ischemic cardiovascular event is reduced blood supply to the muscles of the heart).

The patient should be aware and notify the physician of any changes in how they feel, particularly paying attention to bone pain, chest pain, or liver pain (upper right quadrant).

The way to monitor these risks are through the following:
- bone density test
- complete blood cell counts (CBC)
- monitoring cholesterol and liver function tests
- thyroid function tests
- monitoring serum electrolytes
- kidney function, and blood pressure.


There will also be the physical assessment of the patient and monitoring for the postmenopausal women taking anastrozole. This will include blood pressure readings, pain assessment, gastrointestinal upsets, and hot flashes.

When initiating anastrozole treatment patients may experience dizziness and fatigue. Until your body adjusts be cautious before performing work that requires mental alertness, such as driving.

For more information, see the following link:
http://www.rxlist.com/arimidex-drug.htm